Cost-effectiveness Analysis of Four Different Drugs for Benign Prostatic Hypertrophy
- VernacularTitle:4种治疗良性前列腺增生症药物的成本-效果分析
- Author:
Chengchun SUN
;
Junwen HAO
- Publication Type:Journal Article
- Keywords:
cost-effectiveness analysis;
benign prostatic hypertrophy;
pharmacoeconomics
- From:
China Pharmacy
2001;0(07):-
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To evaluate the economic effectiveness of different therapeutic schemes for benign prostatic hypertrophy METHODS:175 patients with benign prostatic hypertrophy were divided into 4 groups:A,B,C and D They received different drugs,A:tamsulosin(34),B:prostat(45),C:tedenan(46) and D:qiangliexin(50) RESULTS:The costs of A,B,C,D schemes were RMB 492 80,499 52,526 40 and 664 16 yuans,respectively,and the effective ratios were 85 3%,82 2%,80 4% and 80 0%,respectively CONCLUSION:According to the evaluation with pharmacoeconomic cost-effectiveness analysis,A is the best scheme
